Fortress Biotech, Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| FBIO | LLY | |
|---|---|---|
| Market Cap | $92.68 million | $1.04 trillion |
| Revenue (TTM) | $66.16 million | $65.18 billion |
| Net Income (TTM) | $128.94 million | $20.64 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| FBIO | LLY | |
|---|---|---|
| P/E Ratio | 0.88 | 50.97 |
| Price / Book | 0.46 | 39.31 |
| Price / Sales | 1.40 | 16.01 |
FBIO leads on 3 of 3 valuation factors.
Profitability
| FBIO | LLY | |
|---|---|---|
| Net Margin | 194.89% | 31.67% |
| Return on Equity | 63.71% | 77.78% |
FBIO and LLY split the profitability factors evenly.
Dividend
| FBIO | LLY | |
|---|---|---|
| Dividend Yield | — | 0.59% |
| Payout Ratio | — | 30.15 |
FBIO and LLY split the dividend factors evenly.
Risk & Sentiment
| FBIO | LLY | |
|---|---|---|
| Short Interest | 3.18% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: FBIO overview, FBIO financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
